The optimal radiotherapeutic approach to treat clinically localized prostate cancer is yet to be established. Current modern radiotherapeutic options involve either the primary use of external beam radiation therapy or the delivery of interstitial brachytherapy. The state-of-the-art techniques consist of three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), or image-guided transperineal brachytherapy (IGTPB). There are several purported models used in risk appropriation for men with prostate cancer. For patients with clinically localized prostate cancer, the serum prostate-specific antigen (PSA), tumor Gleason score, and tumor stage are widely available and are useful in combination to stratify outcome. Comparison of morbidity between 3D-CRT and IGTPB has been limited because of the lack of consistent toxicity scoring guidelines and stratification criteria. There is a limited number of reports of health-related quality of life after prostate cancer treatment comparing IGTPB with 3D-CRT. Appropriate patient selection is important for radical local treatment and to determine the optimal radiotherapeutic technique.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)